Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the thera...Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the therapeutic mechanism of Shenkangling (肾康灵,SKL) Granule in children. Methods: Sixty children suffering from FRNS were randomly divided into the treated group and control group, 30 in each, and the other 30 healthy children were taken as healthy group. The patients were treated with prednisone for a long-term course, and those with no effect or partial effect shown were treated with additional Tripterygium or Cytoxan in the control group, while in the treated group patients were treated with prednisone and additional SKL. The two groups were compared as to their changes of TNF-a, NO before and after treatment, and the relapses after treatment. Results: The levels of TNF-a and NO in the sick children before treatment were markedly higher than those after treatment and normal group (P< 0. 01). The positive correlation between TNF-o of FRNS cases and relapse risk displayed more significance than that between the relapse of FRNS and NO. The difference between treated group and control group was significant (P<0. 01). Conclusion: TNF-a can be regarded as the monitoring parameter of the active phase in FRNS, and the higher the level, the more possible the relapse would occur. SKL could markedly reduce the relapse rate of FRNS in children.展开更多
目的观察益肾活血等治法对阿霉素肾病(AN)大鼠的干预作用及与核因子κB(NF-κB)、血栓素A_2(TXA_2)和6-酮前列腺素 F_(1α)(6-Keto-PGF_(1α))等关系,旨在探讨肾虚血瘀证在原发性肾病综合征(PNS)发病中的机制及益肾活血法干预治疗的机...目的观察益肾活血等治法对阿霉素肾病(AN)大鼠的干预作用及与核因子κB(NF-κB)、血栓素A_2(TXA_2)和6-酮前列腺素 F_(1α)(6-Keto-PGF_(1α))等关系,旨在探讨肾虚血瘀证在原发性肾病综合征(PNS)发病中的机制及益肾活血法干预治疗的机理。方法用阿霉素诱导大鼠类似于人类微小病变型肾病(MCD)模型,用泼尼松加肾康灵组治疗,并设泼尼松加知柏地黄汤组和泼尼松加桃红四物汤组为对照组。检测各组治疗前后 NF-κB,血、尿液 TXB_2和6-keto-PGF_(1α)及肾脏病理形态学等。结果益肾活血中药肾康灵组在降低尿蛋白、提高血清白蛋白(Alb)、降低胆固醇(Ch)和甘油三酯(TG)、减轻肾脏病理损害等作用方面均优于单纯泼尼松组。结论尾静脉注射阿霉素(ADR)造成的人类肾病病理模型,其临床表现和实验指标改变类似于中医的“肾虚血瘀”病变;益肾活血中药肾康灵能显著改善 AN 鼠的肾虚血瘀证表现和实验指标;激素配合益肾活血法中药干预 AN 鼠的疗效在一定程度上强于单纯激素疗法。展开更多
文摘目的观察肾康灵对TGF-β1干预后肾小管上皮细胞内E-cadherin、α-SMA表达,探讨其抗肾间质纤维化机制。方法采用Western bloting法、RP-PCR法观察空白组、TGF-β1组、肾康灵组的α-SMA、E-cadherin的表达。实验结果采用SPSS 23.0进行统计。结果肾康灵可下调α-SMA、上调E-cadherin m RNA的表达水平,对比TGF-β1组,差异具有统计学意义(P<0.05)。结论肾康灵通过下调α-SMA,上调E-cadherin的水平,缓解肾间质纤维化。
文摘Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the therapeutic mechanism of Shenkangling (肾康灵,SKL) Granule in children. Methods: Sixty children suffering from FRNS were randomly divided into the treated group and control group, 30 in each, and the other 30 healthy children were taken as healthy group. The patients were treated with prednisone for a long-term course, and those with no effect or partial effect shown were treated with additional Tripterygium or Cytoxan in the control group, while in the treated group patients were treated with prednisone and additional SKL. The two groups were compared as to their changes of TNF-a, NO before and after treatment, and the relapses after treatment. Results: The levels of TNF-a and NO in the sick children before treatment were markedly higher than those after treatment and normal group (P< 0. 01). The positive correlation between TNF-o of FRNS cases and relapse risk displayed more significance than that between the relapse of FRNS and NO. The difference between treated group and control group was significant (P<0. 01). Conclusion: TNF-a can be regarded as the monitoring parameter of the active phase in FRNS, and the higher the level, the more possible the relapse would occur. SKL could markedly reduce the relapse rate of FRNS in children.
文摘目的观察益肾活血等治法对阿霉素肾病(AN)大鼠的干预作用及与核因子κB(NF-κB)、血栓素A_2(TXA_2)和6-酮前列腺素 F_(1α)(6-Keto-PGF_(1α))等关系,旨在探讨肾虚血瘀证在原发性肾病综合征(PNS)发病中的机制及益肾活血法干预治疗的机理。方法用阿霉素诱导大鼠类似于人类微小病变型肾病(MCD)模型,用泼尼松加肾康灵组治疗,并设泼尼松加知柏地黄汤组和泼尼松加桃红四物汤组为对照组。检测各组治疗前后 NF-κB,血、尿液 TXB_2和6-keto-PGF_(1α)及肾脏病理形态学等。结果益肾活血中药肾康灵组在降低尿蛋白、提高血清白蛋白(Alb)、降低胆固醇(Ch)和甘油三酯(TG)、减轻肾脏病理损害等作用方面均优于单纯泼尼松组。结论尾静脉注射阿霉素(ADR)造成的人类肾病病理模型,其临床表现和实验指标改变类似于中医的“肾虚血瘀”病变;益肾活血中药肾康灵能显著改善 AN 鼠的肾虚血瘀证表现和实验指标;激素配合益肾活血法中药干预 AN 鼠的疗效在一定程度上强于单纯激素疗法。
